Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Arthritis Research & Therapy
Erschienen in: Arthritis Research & Therapy 5/2003

01.10.2003 | Review

A review of anabolic therapies for osteoporosis

verfasst von: Nancy E Lane, Ariella Kelman

Erschienen in: Arthritis Research & Therapy | Ausgabe 5/2003

Einloggen, um Zugang zu erhalten

Abstract

Osteoporosis results from a loss of bone mass and bone structure such that the bone becomes weak and fractures with very little trauma. Until recently, the approved osteoporosis therapies prevented more bone loss by altering osteoclast activity and lifespan. Recently, attention has turned away from osteoclast inhibition to agents that can stimulate the osteoblast to form new bone, or anabolic agents. This article reviews both approved and experimental anabolic agents that improve bone mass by improving osteoblast activity, or increasing osteoblast number. The use of the anabolic agents to improve bone mass and strength followed by agents that prevent the new bone mass from being lost may offer the ability to cure osteoporosis and reduce bone fracture healing time.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Lee CA, Einhorn TA: Introduction to normal bone physiology and pathophysiology. In Osteoporosis. Edited by: Marcus R, Feldman D, Kelsey J. 2001, San Francisco, CA: Academic Press, 3-19. 2CrossRef
2.
Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE: Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996, 348: 1535-1541. 10.1016/S0140-6736(96)07088-2.CrossRefPubMed
3.
Chesnut CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures. Am J Med. 2000, 109: 267-276. 10.1016/S0002-9343(00)00490-3.CrossRefPubMed
4.
Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999, 282: 637-645. 10.1001/jama.282.7.637.CrossRefPubMed
5.
Rubin MR, Bilizekin JP: New anabolic therapies for osteoporosis. Curr Opin Rheumatol. 2002, 14: 433-440. 10.1097/00002281-200207000-00018.CrossRefPubMed
6.
Crandall C: Parathyroid hormone for treatment of osteoporosis. Arch Intern Med. 2002, 162: 2297-2309. 10.1001/archinte.162.20.2297.CrossRefPubMed
7.
Albright F, Aub JC, Bauer W: Hyperparathyroidism: a common and polymorphic condition illustrated by seventeen proven cases from one clinic. JAMA. 1934, 102: 1276-1287.CrossRef
8.
Albright F, Reifenstein EC: The Parathyroid Glands and Metabolic Bone Disease. Baltimore: Williams & Wilkins. 1948
9.
Hock JM, Gera I, Fonseca J, Raisz LG: Human parathyroid hormone (1–34) increases bone mass in ovariectomized and orchidectomized rats. Endocrinology. 1988, 122: 2899-2904.CrossRefPubMed
10.
Lane NE, Thompson JM, Strewler G, Kinney JH: Intermittent treatment with human parathyroid hormone (hPTH 1–34) increased trabecular bone mass but not connectivity in osteopenic rats. J Bone Miner Res. 1995, 10: 1470-1477.CrossRefPubMed
11.
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH: Effect of parathyroid hormone (-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001, 344: 1434-1441. 10.1056/NEJM200105103441904.CrossRefPubMed
12.
Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R: Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res. 2001, 16: 1846-1853.CrossRefPubMed
13.
Whitfield JF: How to grow bone to treat osteoporosis and mend fractures. Curr Rheumatol Rep. 2003, 5: 45-56.CrossRefPubMed
14.
Lane NE, Yao W, Kinney JH, Modin G, Baloosh M, Wronski TJ: Both hPTH (1–34) increase trabecular bone mass in osteopenic rats however they have different effects on trabecular bone structure. J Bone Min Res. 2003,
15.
Lane N, Yao W, Arnaud C: Association of serum RANKL and OPG levels with other biochemical markers of bone turnover in glucocorticoid-induced osteoporosis patients treated with hPTH (1–34) [abstract]. J Bone Miner Res. 2002, Suppl 1: F366.
16.
Lane NE, Yao W, Arnaud CD: Changes in serum RANKL, OPG and IL-6 during hPTH (1–34) administration in patients with glucocorticoid induced osteoporosis. J Bone Miner Res. 2003,
17.
Mitnick MA, Grey A, Masiukiewicz U, Bartkiewicz M, Rios-Velez L, Friedman S, Xu L, Horowitz MC, Insogna K: Parathyroid hormone induces hepatic production of bioactive IL-6 and its soluble receptor. Am J Physiol Endocrinol Metab. 2001, 280: E405-E412.PubMed
18.
Greenfield EM, Horowitz Lavish SA: Stimulation of parathyroid hormone of interleukin-6 and leukemia inhibitory factor expression in osteoblasts is an immediate-early gene response induced by cAMP signal transduction. J Biol Chem. 1996, 271: 10984-10989. 10.1074/jbc.271.18.10984.CrossRefPubMed
19.
Fu Q, Jilka RL, Manolagas SC, O'Brien CA: Parathyroid hormone stimulates receptor activator of NFkB ligand and inhibits osteoprotegrin expression via protein kinase A activation of cAMP-response element binding protein. J Biol Chem. 2002, 277: 48868-48875. 10.1074/jbc.M208494200.CrossRefPubMed
20.
Lee S-K, Lorenzo JA: Parathyroid hormone stimulates TRANCE and inhibits osteoprotegrin messenger ribonucleic acid expression with osteoclast-like cell formation. Endocrinology. 1999, 140: 3552-3561. 10.1210/en.140.8.3552.PubMed
21.
Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM: Intermittently administered human parathyroid hormone (1–34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res. 2001, 16: 157-165.CrossRefPubMed
22.
Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP: Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab. 2000, 85: 3069-3076. 10.1210/jc.85.9.3069.PubMed
23.
Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA: The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003, 18: 9-17.CrossRefPubMed
24.
Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F: Randomized controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 1997, 350: 550-555. 10.1016/S0140-6736(97)02342-8.CrossRefPubMed
25.
Roe E, Sanchez S, del puerto G: Parathyroid hormone 1–34 (hPTH 1–34) and estrogen produce dramatic bone density increases in postmenopausal osteoporosis-results from a placebo-controlled randomized trial [abstract]. J Bone Miner Res. 1999, Suppl 1: S137.
26.
Cann C, Roe EB, Sanchez SD: PTH effect in the femur: envelope-specific responses by 3DQCT in postmenopausal women [abstract]. J Bone Miner Res. 1999, Suppl 1: S137.
27.
Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ: Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab. 2000, 85: 2129-2134. 10.1210/jc.85.6.2129.PubMed
28.
Black DM, Rosen C, Greenspan S, Ensrud K, Bilezikian J, McGowan J: PTH and bisphosphonates in the treatment of osteoporosis: design of the PTH and alendronate (PATH) trial [abstract]. In ASBMR 23rd annual meeting. 2001, 5287.
29.
Finkelstein JS, Hayes A, Rao A, Neer RM: Effects of parathyroid hormone, alendronate or both on bone mineral density in osteoporotic men [abstract]. J Bone Miner Res. 2002, Suppl 1: 1007.
30.
Neer R, Hayes A, Rao A, Finkelstein J: Effects of parathyroid hormone, alendronate, or both on bone density in osteoporotic postmenopausal women [abstract]. J Bone Miner Res. 2002, Suppl 1: 1039.
31.
Ettinger B, San Martin JA, Crans G, Pavo I: Early response of bone turnover markers and bone mineral density to teriparatide (rhPTH 1–34) in postmenopausal women previously treated with an anti-resorptive agent [abstract]. J Bone Miner Res. 2002, Suppl 1: 1136.
32.
Horwitz M, Stewart A, Greenspan SL: Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab. 2003, 88: 569-575. 10.1210/jc.2002-021122.CrossRefPubMed
33.
Wuster C, Rosen C: Growth hormone, insulin-like growth factors. Potential applications and limitations in the management of osteoporosis. In Osteoporosis. Edited by: Marcus R, Feldman D, Kelsey J. 2001, San Francisco, CA: Academic Press, 747-767. 2CrossRef
34.
Rosen T, Wilhelmsen L, Landin-Wilhelmsen K, Lappas G, Bengtson B-A: Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol. 1997, 137: 240-245. 10.1530/eje.0.1370240.CrossRefPubMed
35.
Wuster C, Abs R, Bengtsson B-A, Bennmarker H, Feldt-Rasmussen U, Hernberg-Stahl E, Monsom JP, Westberg B, Wilton P: The incidence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopi-tuitarism on fracture rate and bone mineral density. J Bone Miner Res. 2001, 16: 398-405.CrossRefPubMed
36.
Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Gold-berg AF, Schlenkler RA, Cohn L, Rudman IW, Mattson DE: Effects of human growth hormone in men over 60 years old. N Engl J Med. 1990, 323: 1-6.CrossRefPubMed
37.
Yakar S, Rosen CJ: From mouse to man: redefining the role of insulin-like growth factor-I in the acquisition of bone mass. Proc Soc Exp Biol Med. 2003, 228: 245-252.
38.
Hankinson SE, Willet WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998, 351: 1393-1396. 10.1016/S0140-6736(97)10384-1.CrossRefPubMed
39.
Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst. 1999, 91: 620-625. 10.1093/jnci/91.7.620.CrossRefPubMed
40.
Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M: Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science. 1998, 279: 563-566. 10.1126/science.279.5350.563.CrossRefPubMed
41.
Landin-Wilhelmsen K, Nilsson A, Bosaeus I, Bengtsson B: Growth hormone increases bone mineral content in postmenopausal osteoporosis: a randomized placebo-controlled trial. J Bone Miner Res. 2003, 18: 393-405.CrossRefPubMed
42.
Reginster JY: Strontium ranelate in osteoporosis. Curr Pharm Des. 2002, 8: 1907-1916. 10.2174/1381612023393639.CrossRefPubMed
43.
Marie PJ, Hott M, Modrowski D, De Pollack C, Guillemain J, Deloffre P, Tsouderos Y: An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res. 1993, 8: 607-615.CrossRefPubMed
44.
Reginster JY, Deroisy R, Dougados M, Jupsin I, Colette J, Roux C: Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial. Osteoporos Int. 2002, 13: 925-931. 10.1007/s001980200129.CrossRefPubMed
45.
Reginster JY, Hoszowski K, Roces Varela A, Balogh A, Clements M, Fiore C, Cormier C, Schmidt WE, Jensen JB, Prince R, Raeman F, Rizzoli R, Meunier PJ: Strontium ranelate: a new effective antiosteoporotic treatment reducing the incidence of vertebral and non vertebral fractures in postmenopausal women with osteoporosis. In International Osteoporosis Society meeting. Osaka, Japan. 2003,
46.
Meunier PJ, Reginster JY: Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis. Osteoporos Int. 2003, Suppl 3: 66-76.
47.
Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G: Stimulation of bone formation in vitro and in rodents by statins. Science. 1999, 286: 1546-1549. 10.1126/science.286.5446.1946.CrossRef
48.
Garrett IR, Gutierrez G, Chen D: Statins stimulate bone formation by enhancing eNOS expression [abstract]. J Bone Miner Res. 2001, 16: S141-10.1016/S0929-1393(00)00114-1.CrossRef
49.
van't Hof RJ, Ralston SH: Nitric oxide and bone. Immunology. 2001, 103: 113-118. 10.1046/j.1365-2567.2001.01261.x.CrossRef
50.
Ohnaka K, Shimoda S, Nawata H, Shimokawa H, Kaibuchi K, Iwamoto Y, Takayanagi R: Pitavastatin-enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem Biophys Res Commun. 2001, 287: 337-342. 10.1006/bbrc.2001.5597.CrossRefPubMed
51.
Wang GJ, Chung KC, Shen WJ: Lipid-clearing agents in steroid-induced osteoporosis. J Formos Med Assoc. 1995, 94: 589-592.PubMed
52.
Cosman F, Nieves J, Zion M: Effects of short-term cerivastatin on bone turnover [abstract]. J Bone Miner Res. 2001, 16: S29.CrossRef
53.
54.
Bauer DC: HMG CoA reductase inhibitors and the skeleton: a comprehensive review. Osteoporos Int. 2003, 4: 273-282. 10.1007/s00198-002-1323-x.CrossRef
55.
Reid IR, Hague W, Emberson J, Baker J, Tonkin A, Hunt D, MacMahon S, Sharpe N: Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravas-tatin in Ischaemic Disease. Lancet. 2001, 357: 509-512. 10.1016/S0140-6736(00)04042-3.CrossRefPubMed
56.
LaCroix AZ, Cauley JA, Pettinger M, Hsia J, Bauer DC, McGowan J, Chen Z, Lewis CE, McNeeley G, Passaro MD, Jackson RD: Statin use, clincal fracture, and bone mineral density in postmenopausal women: Results from the women's health initiative observational study. Annal Int Med. 2003, 139: 97-104.CrossRef
57.
Locklin RM, Oreffo ROC, Triffit JT: Effects of TGFB and bFGF on the differentiation of human bone marrow stromal fibroblasts. Cell Biol Int. 1999, 23: 185-194. 10.1006/cbir.1998.0338.CrossRefPubMed
58.
Saadeh PB, Mehrara BJ, Steinbrech DS, Dudziak ME, Greenwald JA, Luchs JS, Spector JA, Ueno H, Gittes GK, Longaker MT: Transforming growth factor-B1 modulates the expression of vascular endothelial growth factor by osteoblasts. Am J Physiol. 1999, 277: C628-C637.PubMed
59.
Nagai H, Tsukuda R, Mayahara H: Effects of basic fibroblast growth factor (bFGF) on bone formation in growing rats. Bone. 1995, 16: 367-373. 10.1016/8756-3282(94)00049-2.CrossRefPubMed
60.
Pun S, Florio CL, Wronski TJ: Anabolic effects of basic fibroblast growth factor in the tibial diaphysis of ovariectomized rats. Bone. 2000, 27: 197-202. 10.1016/S8756-3282(00)00312-4.CrossRefPubMed
61.
Wronski TJ, Ratkus AM, Thomsen JS, Vulcan Q, Mosekilde L: Sequential treatment with basic fibroblast growth factor and parathyroid hormone restores lost cancellous bone mass and strength in the proximal tibia of aged ovariectomized rats. J Bone Miner Res. 2001, 16: 1399-1407.CrossRefPubMed
62.
Lane NE, Kumer J, Yao W, Breunig T, Wronski T, Modin G, Kinney JH: Basic fibroblast growth factor forms new trabeculae that physically connect with pre-existing trabeculae, and this new bone is maintained with an anti-resorptive agent and enhanced with an anabolic agent in an osteopenic rat model. Osteoporos Int. 2003, 14: 374-352. 10.1007/s00198-003-1374-7.CrossRefPubMed
63.
Street J, Bao M, deGuzman L, Bunting S, Peale FV, Ferrara N, Steinmetz H, Hoeffel J, Cleland JL, Daugherty A, van Bruggen N, Redmond HP, Carano RAD, Filvaroff EH: Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci USA. 2002, 99: 9656-9661. 10.1073/pnas.152324099.PubMedCentralCrossRefPubMed
64.
Wang EA, Israel DI, Kelly S, Luxenberg DP: Bone morphogenetic protein-2 causes commitment and differentiation in C3h10T1/2 and 3T3 cells. Growth Factors. 1993, 9: 57-71.CrossRefPubMed
65.
Ahrens M, Ankenbauer T, Schroder D, Hollnagel A, Mayer H, Gross G: Expression of human bone morphogenetic proteins -2 or -4 in murine mesenchymal progenitor C3H10T1/2 cells induces differentiation into distinct mesenchymal cell lineages. DNA Cell Biol. 1993, 12: 871-880.PubMed
66.
Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimuzu Y, Bronson RT, Gao YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S., Kishimoto T: Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 1997, 89: 755-764. 10.1016/S0092-8674(00)80258-5.CrossRefPubMed
67.
Onishi T, Ishidou Y, Nagamine T, Yone K, Imamura T, Kato M, Sampath TK, ten Dijke P, Sakou T: Distinct and overlapping patterns of localization of bone morphogenetic protein (BMP) family members and a BMP type II receptor during fracture healing in rats. Bone. 1998, 22: 605-612. 10.1016/S8756-3282(98)00056-8.CrossRefPubMed
68.
Welch RD, Jones Al, Bucholz RW, Reinert CM, Tjia JS, Pierce WA, Wozney JM, Li XJ: Effect of recombinant human bone morphogenetic protein-2 on fracture healing in a goat tibial fracture model. J Bone Miner Res. 1998, 13: 1483-1490.CrossRefPubMed
69.
Bouxsein ML, Turek TJ, Blake CA, D'Augusta D, Li X, Stevens M, Seeherman HJ, Wozney JM: Recombinant human bone morphogenetic protein-2 accelerates healing in a rabbit ulnar osteotomy model. J Bone Joint Surg. 2001, 83-A: 1219-1230.PubMed
70.
Govender S, Csimma C, Genant HK, Valentin-Opran A: Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures. J Bone Joint Surg. 2002, 84-A: 2123-2134.PubMed
71.
Burkus JK, Transfeldt EE, Kitchel SH, Watkins RG, Balderstom RA: Clinical and radiographic outcomes of anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2. Spine. 2002, 27: 2396-2408. 10.1097/00007632-200211010-00015.CrossRefPubMed
72.
BMP 2–Genetics Institute/ Medtronic-Sofamor Danek/Integra. Bone morphogenetic protein 2–Genetics Institute/ Medtronic-Sofamor Danek/Integra, INFUSE Bone Graft, recombinant human bone morphogenetic protein 2–Genetics Institute/Medtronic-Sofamor Danek/Integra, RhBMP 2–Genetics Institute/Medtronic-Sofamor Danek/Integra. BioDrugs. 2002, 16: 376-377.
73.
Barnes GL, Kostenuik PJ, Gerstenfeld LC, Einhorn TA: Growth factor regulation of fracture repair. J Bone Miner Res. 1999, 14: 1805-1815.CrossRefPubMed
74.
Reddi AH: Bone morphogenetic proteins: from basic science to clinical applications. J Bone Joint Surg Am. 2001, Suppl 1 (Pt 1): S1-6.
75.
Geesink RG, Hoefnagels NH, Bulstra SK: Osteogenic activity of OP-1 bone morphogenic protein (BMP-7) in a human fibular defect. J Bone Joint Surg Br. 1999, 81: 710-718. 10.1302/0301-620X.81B4.9311.CrossRefPubMed
76.
Friedlaender GE, Perry CR, Cole JD, Cook SD, Cierny G, Muschler GF, Zych GA, Calhoun JH, LaForte AJ, Yin S: Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am. 2001, Suppl 1 (Pt 2): S151-S158.
77.
Cook SD, Dalton JE, Tan EH, Whitecloud TS, Rueger DC: In vivo evaluation of recombinant human osteogenic protein (rhOP-1) implants as a bone graft substitute for spinal fusions. Spine. 1994, 19: 1655-1663.CrossRefPubMed
78.
Margolin MD, Cogan AG, Taylor M, Buck D, McAllister TN, Toth C, McAllister BS: Maxillary sinus augmentation in the non-human primate: a comparative radiographic and histologic study between recombinant human osteogenic protein-1 and natural bone mineral. J Periodontol. 1998, 69: 911-919.CrossRefPubMed
79.
Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, Cedel SL, Melton LJ: Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med. 1990, 322: 802-809.CrossRefPubMed
80.
Kleerekoper M, Peterson EL, Nelson DA, Phillips E, Schork MA, Tilley BC, Parfitt AM: A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporos Int. 1991, 1: 155-161. 10.1007/BF01625446.CrossRefPubMed
81.
Pak CY, Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR: Treatment of postmenopausal osteoporosis with slow-release sodium fluoride: final report of a randomized controlled trial. Ann Intern Med. 1999, 123: 401-408.CrossRef
82.
Ringe JD, Rovati LC: Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates. Calcif Tissue Int. 2001, 69: 252-255. 10.1007/s00223-001-1050-x.CrossRefPubMed
Metadaten
Titel
A review of anabolic therapies for osteoporosis
verfasst von
Nancy E Lane
Ariella Kelman
Publikationsdatum
01.10.2003
Verlag
BioMed Central
Erschienen in
Arthritis Research & Therapy / Ausgabe 5/2003
Elektronische ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar797

Weitere Artikel der Ausgabe 5/2003

Arthritis Research & Therapy 5/2003 Zur Ausgabe

Review

Ageing, autoimmunity and arthritis: T-cell senescence and contraction of T-cell repertoire diversity – catalysts of autoimmunity and chronic inflammation

Research article

Prevalence, clinical relevance and characterization of circulating cytotoxic CD4+CD28- T cells in ankylosing spondylitis

Viewpoint

Interpreting interest in interferon-α

Research article

Vγ9/Vδ2 T lymphocytes in Italian patients with Behçet's disease: evidence for expansion, and tumour necrosis factor receptor II and interleukin-12 receptor β1 expression in active disease

Review

Ageing, autoimmunity and arthritis: An introduction

Research article

Differentiation of naive CD4+ T cells towards T helper 2 cells is not impaired in rheumatoid arthritis patients

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise